Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Cowie, M.R.; Simon, M.; Klein, L.; Thokala, P. (2017)
Publisher: Wiley
Languages: English
Types: Article
AIMS: Heart failure (HF) treatment guided by physicians with access to real-time pressure measurement from a wireless implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF-related hospital admissions in the CHAMPION trial. However, uncertainty remains regarding the value of CardioMEMS in European health systems where healthcare costs are significantly lower than in the USA. METHODS AND RESULTS: A Markov model was developed to estimate the cost-effectiveness of PAP-guided treatment of HF using the CardioMEMS™ HF system compared with usual care. Cost-effectiveness was measured as the incremental cost per quality-adjusted life year (QALY) gained. In the base case analysis over a time horizon of 10 years, PAP-guided HF therapy increased cost compared with usual care by £10 916 (€14 030). QALYs per patient for usual care and PAP-guided patients were 2.57 and 3.14, respectively, reflecting an increase of 0.57 QALYs with PAP-guided treatment. The resultant incremental cost-effectiveness ratio (ICER) is £19 274 (€24 772) per QALY gained. The base case analysis did not include staff time, due to a lack of data concerning this variable. Running the model with estimated staff time included resulted in an increased ICER of between £22 342 and £25 464 per QALY gained (€28 709-32 721). CONCLUSION: The analysis indicates that integrating wireless PAP monitoring into the management of UK HF patients is likely to be a cost-effective addition to the HF treatment pathway for appropriate patients.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146.
    • 2. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515-523.
    • 3. Jeon YH, Kraus SG, Jowsey T, Glasgow NJ. The experience of living with chronic heart failure: a narrative review of qualitative studies. BMC Health Serv Res 2010;10:77.
    • 4. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M. Cardiovascular Disease Statistics 2015. British Heart Foundation; 2015.
    • 5. Mitchell P, Marle D, Akosua D, Shote A, McDonagh T, Hardman S, Dargie HJ, Cleland J. National Heart Failure Audit Report. NICOR; 2015
    • 6. National Institute for Health and Care Excellence. Chronic heart failure. Costing report. https://www.nice.org.uk/guidance/cg108/resources/cg108-chronic-heartfailure-costing-report2.
    • 7. Heart failure - sacubitril valsartan [ID822] | Guidance and guidelines: Committee Papers | NICE. https://www.nice.org.uk/guidance/indevelopment/gid-tag516/ documents.
    • 8. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13 Suppl 2:ii13-ii17.
    • 9. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-169.
    • 10. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119(12 Suppl 1):S3-S10.
    • 11. Kato M, Stevenson LW, Palardy M, Campbell PM, May CW, Lakdawala NK, Stewart G, Nohria A, Rogers JG, Heywood JT, Gheorghiade M, Lewis EF, Mi X, Setoguchi S. The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. J Card Fail 2012;18:524-533.
    • 12. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114:625-630.
    • 13. Food and Drug Administration. CardioMEMS Champion HF Monitoring System PMA Amendment P100045. FDA and CardioMEMS Panel Package. Prepared for the October 9, 2013 Circulatory System Devices Panel Meeting. 2013; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystem DevicesPanel/UCM370692.pdf.
    • 14. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
    • 15. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS, CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-666.
    • 16. Klersy C, De Silvestri A, Gabutti G, Raisaro A, Curti M, Regoli F, Auricchio A. Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail 2011;13:450-459.
    • 17. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart 2014;100:1031-1036.
    • 18. Berg J, Lindgren P, Mejhert M, Edner M, Dahlstrom U, Kahan T. Determinants of utility based on the EuroQol five-dimensional questionnaire in patients with
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article